FDA Approves Zykadia for Metastatic NSCLC

Share this content:
FDA Approves Zykadia for Metastatic NSCLC
FDA Approves Zykadia for Metastatic NSCLC

The FDA has granted accelerated approval to Zykadia (ceritinib; Novartis) in patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Zykadia is an ALK tyrosine kinase inhibitor that blocks proteins that promote tumor development. Ceritinib actively inhibits autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitro and in vivo assays. Zykadia is the second approved ALK tyrosine kinase inhibitor after crizotinib.

RELATED: Ceritinib Demonstrates Strong Response in ALK-positive NSCLC

Zykadia was granted breakthrough therapy designation, priority review, and orphan product designation following substantial preliminary clinical data. Its safety and effectiveness were established in a clinical trial of 163 patients with metastatic ALK-positive NSCLC. All participants were treated with Zykadia and about half of the patients had their tumors shrink for an average of 7 months.

Zykadia will be available in 150mg hard gel capsules in 70-count bottles.

For more information call (888) 669-6682 or visit Novartis.com.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs